文献速递心力衰竭与心肌病

静脉羧基麦芽糖铁在缺铁性心力衰竭中的年龄分层效应:IRONMAN 试验分析

Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial.
PubMed 文献 · Heart · 2025-06-13

IRONMAN 试验预设分析按年龄四分位分层,评估静脉羧基麦芽糖铁(FDI)在 1137 例 HFrEF 合并缺铁患者中的疗效与安全性。各年龄组主要复合终点率比无显著交互作用(p-interaction=0.38),4 个月血红蛋白和生活质量改善亦无年龄差异,安全性无差异。结果支持 FDI 在各年龄组包括高龄患者中使用。

要点

  • 各年龄组 FDI 对心衰住院和心血管死亡的主要复合终点效应无显著交互作用。
  • 4 个月血红蛋白和生活质量改善在各年龄组间无统计学差异。
  • 高龄患者基线症状更重、NT-proBNP 更高、肾功能更差,但安全性无年龄差异。

核心结论

  • 未发现 FDI 对心衰住院、心血管死亡、血红蛋白和生活质量的影响因年龄而异,支持其在包括高龄在内的 HFrEF 合并缺铁患者中使用。

研究设计与样本

  • IRONMAN 试验为前瞻性、开放标签、盲法终点随机对照试验,纳入 HFrEF 合并缺铁患者 1137 例(中位年龄 73 岁)。
  • 本预设分析按年龄四分位分为 <67 岁、67-73 岁、74-79 岁、>79 岁四组。
  • 主要终点为复发性心衰住院和心血管死亡的复合终点,采用 Lin 等方法和 Cox 比例风险模型分析。

主要发现

  • 主要终点率比(FDI vs 常规治疗):<67 岁为 0.87(95%CI 0.61-1.23),67-73 岁为 0.93(95%CI 0.66-1.32),74-79 岁为 0.88(95%CI 0.59-1.33),>79 岁为 0.66(95%CI 0.45-0.96),p-interaction=0.38。
  • 4 个月血红蛋白和生活质量评分改善在各年龄组间无统计学差异(p-interaction 分别为 0.92 和 0.64)。
  • 高龄患者基线症状更重、NT-proBNP 水平更高、肾功能更差,但安全性结局在各年龄组间无差异。

临床怎么用

  • 对于 HFrEF 合并缺铁的患者,包括高龄患者,可考虑使用静脉羧基麦芽糖铁治疗。
  • 年龄不应作为限制 FDI 使用的依据,但需注意高龄患者基线症状和肾功能更差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. However, its effects across different age groups remain unclear. This analysis of the Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency (IRONMAN) trial explored the efficacy and safety of FDI across age groups. METHODS: The IRONMAN trial was a prospective, open-label, blinded end point randomised controlled trial enrolling patients with HFrEF and iron deficiency. This prespecified analysis stratified the population into four quarters by age group: <67 years, 67-73 years, 74-79 years, >79 years. The primary outcome was a composite of recurrent heart failure hospitalisations and cardiovascular death. Secondary outcomes included changes in haemoglobin and quality of life. Clinical outcomes comparing FDI versus usual care in each age subgroup were analysed by the method of Lin et al for recurrent events and Cox proportional hazards model for time to first event. Interactions between age and treatment effects were explored. RESULTS: Among 1137 randomised patients (median age 73 years), the primary outcome rate ratio (FDI vs usual care) was 0.87 (95% CI 0.61 to 1.23) in patients <67 years, 0.93 (95% CI 0.66 to 1.32) in those aged 67-73 years, 0.88 (95% CI 0.59 to 1.33) in those aged 74-79 years and 0.66 (95% CI 0.45 to 0.96) in those aged >79 years (p-interaction=0.38). Improvements in haemoglobin and quality of life scores at 4 months did not differ statistically across age groups (p-interaction=0.92 and 0.64, respectively). Older patients were more symptomatic at baseline, with higher N-terminal-pro B-type natriuretic peptide levels and poorer renal function, but safety outcomes did not differ across age groups. CONCLUSIONS: We found no evidence that the effects of FDI on heart failure hospitalisations, cardiovascular death, haemoglobin and quality of life differed by age. These findings support its use in patients with HFrEF and iron deficiency, including older adults. TRIAL REGISTRATION NUMBER: NCT02642562.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sze, Squire, Kalra, et al. Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial. Heart. 2025. PMID: 39938943. doi:10.1136/heartjnl-2024-324908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。